Ascendis reports Q3 2026 results as CNP therapy clears EU review, trial milestones advance
Ascendis posted Q3 2026 product revenue of 366 million euros and said EU regulators backed its CNP therapy for achondroplasia, with a final decision expected in the fourth quarter.
SEC filing